Two Sigma Investments LP Acquires 50,463 Shares of Edwards Lifesciences Co. (NYSE:EW)

Two Sigma Investments LP raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 67.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 125,032 shares of the medical research company's stock after purchasing an additional 50,463 shares during the period. Two Sigma Investments LP's holdings in Edwards Lifesciences were worth $9,256,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Tidal Investments LLC increased its position in Edwards Lifesciences by 18.8% during the 4th quarter. Tidal Investments LLC now owns 46,970 shares of the medical research company's stock valued at $3,477,000 after buying an additional 7,438 shares in the last quarter. Teza Capital Management LLC grew its stake in shares of Edwards Lifesciences by 13.8% in the fourth quarter. Teza Capital Management LLC now owns 90,836 shares of the medical research company's stock worth $6,725,000 after acquiring an additional 10,997 shares during the last quarter. State of Wyoming increased its holdings in shares of Edwards Lifesciences by 128.2% during the fourth quarter. State of Wyoming now owns 1,935 shares of the medical research company's stock valued at $143,000 after acquiring an additional 1,087 shares in the last quarter. Tema Etfs LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at $1,602,000. Finally, Toronto Dominion Bank raised its position in shares of Edwards Lifesciences by 5.7% in the 4th quarter. Toronto Dominion Bank now owns 317,326 shares of the medical research company's stock worth $23,492,000 after purchasing an additional 17,046 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on EW shares. Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Friday, May 16th. Citigroup reiterated a "buy" rating and set a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a report on Thursday, April 24th. Barclays upped their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus target price of $80.20.

Insider Buying and Selling

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the completion of the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Daveen Chopra sold 1,500 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the sale, the vice president now owns 33,496 shares in the company, valued at $2,514,879.68. This represents a 4.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 56,442 shares of company stock worth $4,025,799. 0.34% of the stock is owned by corporate insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded up $0.40 during midday trading on Friday, hitting $78.13. The stock had a trading volume of 774,677 shares, compared to its average volume of 5,156,741. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The company has a market capitalization of $45.83 billion, a PE ratio of 11.23, a P/E/G ratio of 4.82 and a beta of 1.12. The firm's fifty day moving average is $73.22 and its two-hundred day moving average is $72.33. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same period in the prior year, the company posted $0.66 earnings per share. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. On average, research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.